Evaluation of microscan walkaway and vitek 2 for determination of the susceptibility of extended-spectrum Β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2282-2285

  Jang, Woori ^a   Park, Yeon Joon ^a   Park, Kang Gyun ^a   Yu, Jinkyung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Antimicrobial susceptibility testing; Cephalosporins; CLSI; ESBLs; EUCAST

Indexed keywords

CEFEPIME; CEFOTAXIME; CEFTAZIDIME; EXTENDED SPECTRUM BETA LACTAMASE;

ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; EVALUATION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; GENOTYPE; HOSPITAL; KOREA; NONHUMAN; POLYMERASE CHAIN REACTION;

ANTIMICROBIAL SUSCEPTIBILITY TESTING; CEPHALOSPORINS; CLSI; ESBLS; EUCAST;

AUTOMATION, LABORATORY; BETA-LACTAMASES; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORINS; DIAGNOSTIC ERRORS; DNA, BACTERIAL; ESCHERICHIA COLI; GENOTYPE; HOSPITALS; HUMANS; KLEBSIELLA PNEUMONIAE; KOREA; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION;

EID: 84888778417     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt172     Document Type: Article

References (18)

1. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI,Wayne, PA, USA, 2012.
2. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 2.0. January 2012. http://www.eucast.org/clinical_breakpoints/(15 January 2013, date last accessed).
3. Nogueira Kda S, Daur AV, Reason IT et al. Cefepime versus extended spectrum b-lactamase-producing Enterobacteriaceae. Braz J Infect Dis 2011; 15: 167-9.
4. Bhavnani SM, Ambrose PG, Craig WA et al. Outcomes evaluation of patients with ESBL-and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006; 54: 231-6.
5. Livermore DM, Andrews JM, Hawkey PM et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 2012; 67: 1569-77.
6. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI,Wayne, PA, USA, 2012.
7. Song W, Bae IK, Lee YN et al. Detection of extended-spectrum b-lactamases by using boronic acid as an AmpC b-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli. J Clin Microbiol 2007; 45: 1180-4.
8. Ryoo NH, Kim EC, Hong SG et al. Dissemination of SHV-12 and CTX-M-type extended-spectrum b-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea. J Antimicrob Chemother 2005; 56: 698-702.
9. Woodford N, Fagan EJ, Ellington MJ. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum b-lactamases. J Antimicrob Chemother 2006; 57: 154-5.
10. Nüesch-InderbinenMT,Hächler H, Kayser FH. Detection of genes coding forextended-spectrumSHVb-lactamases in clinical isolates bya molecular genetic method, and comparison with the E test. Eur J Clin Microbiol Infect Dis 1996; 15: 398-402.
11. Murray PR, Niles AC, Heeren RL. Comparison of a highly automated 5-h susceptibility testing system, the Cobas-Bact, with two reference methods: Kirby-Bauer disk diffusion and broth microdilution. J Clin Microbiol 1987; 25: 2372-7.
12. FDA. Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA. Rockville, MD: FDA, 2007.
13. Garcia LS, Isenberg HD. Clinical Microbiology Procedures Handbook. Washington, DC: ASM Press, 2010.
14. Wang P, Hu F, Xiong Z et al. Susceptibility of extended-spectrum-blactamase-producing Enterobacteriaceae according to the new CLSI breakpoints. J Clin Microbiol 2011; 49: 3127-31.
15. Hawser SP, Badal RE, Bouchillon SK et al. Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study. Int J Antimicrob Agents 2010; 36: 293-4.
16. Lat A, Clock SA, Wu F et al. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol 2011; 49: 1795-8.
17. Bulik CC, Fauntleroy KA, Jenkins SG et al. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol 2010; 48: 2402-6.
18. Espinar MJ, Rocha R, Ribeiro M et al. Extended-spectrum b-lactamases of Escherichia coli and Klebsiella pneumoniae screened by the VITEK 2 system. J Med Microbiol 2011; 60: 756-60.